Abstract
WHEN INDIA'S DR. REDDY'S Laboratories spent $59 million to buy a Mexican pharmaceutical chemical plant from Roche last November, the Indian firm said the move was part of a strategy to expand its custom pharmaceutical chemical business 10-fold. To achieve the target, Dr. Reddy's will also have to convince customers to look past the fact that it is also their legal nemesis. Dr. Reddy's is the Indian generic drug producer that most often challenges larger pharmaceutical companies' patents in U.S. courts to gain market access. In the past few years, Reddy's has gone after the patents of Pfizer, GlaxoSmithKline, Eli Lilly & Co., Novartis, and other companies. Abhijit Mukherjee, a Mukherjee seasoned executive who previously worked at leading consumer goods company Hindustan Lever, is Reddy's president of developing businesses and the person in charge of building up the custom pharmaceutical chemical business. He acknowledges that some potential customers ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
